This study reports the first use of BCMA-CD19 bispecific CAR-T cell therapy in a patient with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), demonstrating significant clinical improvement and sustained remission without relapse after treatment, highlighting the potential of this novel approach for managing difficult-to-treat CIDP cases.